PM
ESPR

Parametrica Management’s Esperion Therapeutics ESPR Stock Holding History

Parametrica Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,753
Closed -$213K – 177
2020
Q1 		$213K Buy
+6,753
New +$356K 0.22% 168
2016
Q1 		– Sell
-19,912
Closed -$443K – 111
2015
Q4 		$443K Buy
+19,912
New +$502K 2.92% 6

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Parametrica Management's ESPR Position: Q2 2020 in Review

Parametrica Management sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 6,753 shares — an estimated $213K sold.

Parametrica Management first reported a position in ESPR in Q4 2015 and held it in 2 quarters. The position peaked at $443K in Q4 2015. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Parametrica Management reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Parametrica Management sold 6,753 Esperion Therapeutics shares in Q2 2020, an estimated $213K.
  • Parametrica Management first reported a position in Esperion Therapeutics in Q4 2015 and held it in 2 quarters.
  • Parametrica Management's Esperion Therapeutics position peaked at $443K in Q4 2015.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Parametrica Management's 13F filing for Q2 2020, filed 17 Aug 2020.